<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Alpha-<z:chebi fb="0" ids="25271">methylacyl-CoA</z:chebi> racemase (AMACR) is involved in the cellular metabolism of fatty acids </plain></SENT>
<SENT sid="1" pm="."><plain>It is a prognostic factor in prostate and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>So far, little is known about its expression and prognostic role in <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated the expression of AMACR in a total of 420 <z:mp ids='MP_0008000'>ovarian tumors</z:mp> (388 <z:mp ids='MP_0002038'>carcinomas</z:mp>, 32 borderline <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>) by immunohistochemistry on tissue microarrays of two independent patient cohorts </plain></SENT>
<SENT sid="4" pm="."><plain>In both cohorts, cytoplasmic AMACR expression was identified in 11.8% (16/136) and 5.4% (13/239), respectively, of the <z:mp ids='MP_0003579'>ovarian carcinomas</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, borderline <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> did not show any AMACR expression </plain></SENT>
<SENT sid="6" pm="."><plain>AMACR expression was significantly associated with histological subtype, FIGO stage, and grade in one cohort and low <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptor levels in the other cohort </plain></SENT>
<SENT sid="7" pm="."><plain>In univariate analysis, AMACR expression was significantly associated with poor overall survival (log rank, p = 0.006) and an independent prognostic factor in a multivariate analysis (HR 3.3; CI 1.3-7.9; p = 0.008) but could not be verified in the second cohort </plain></SENT>
<SENT sid="8" pm="."><plain>Unlike in other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> entities, AMACR expression does not seem to have an unequivocal prognostic impact in <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The prevalence may limit the value of AMACR for the differential diagnosis between metastatic colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> and primary <z:mp ids='MP_0003579'>ovarian carcinomas</z:mp>, whereas the association with <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptor expression deserves further studies </plain></SENT>
</text></document>